CIP
GOSS icon

Chartwell Investment Partners’s Gossamer Bio GOSS Stock Holding History

Chartwell Investment Partners’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-26,546
Closed -$318K – 412
2022
Q3 		$318K Buy
+26,546
New +$329K 0.01% 400

Other funds holding GOSS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Chartwell Investment Partners's GOSS Position: Q4 2022 in Review

Chartwell Investment Partners sold out of Gossamer Bio (GOSS) in Q4 2022, closing a stake of 26,546 shares — an estimated $318K sold.

Chartwell Investment Partners first reported a position in GOSS in Q3 2022 and held it in 1 quarter. The position peaked at $318K in Q3 2022. 120 funds tracked by Wall St. Rank hold GOSS as of Q4 2022.

  • Chartwell Investment Partners reported no remaining Gossamer Bio position as of Q4 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 26,546 Gossamer Bio shares in Q4 2022, an estimated $318K.
  • Chartwell Investment Partners first reported a position in Gossamer Bio in Q3 2022 and held it in 1 quarter.
  • Chartwell Investment Partners's Gossamer Bio position peaked at $318K in Q3 2022.
  • 120 funds tracked by Wall St. Rank held Gossamer Bio as of Q4 2022.

Based on Chartwell Investment Partners's 13F filing for Q4 2022, filed 16 Feb 2023.